HIFs (Hypoxia-inducible factors) are transcription factors that react to variations in the amount of oxygen available to cells, more specifically, to reductions in oxygen, or hypoxia. The effects of hypoxia, a condition of low oxygen concentration, on the cell are mediated by the HIF signaling cascade. Oftentimes, hypoxia prevents cells from differentiating. However, hypoxia encourages the growth of blood vessels and is crucial for the development of a vascular system in both cancer tumors and embryos.Additionally, the hypoxia in wounds encourages keratinocyte migration and epithelium repair. HIFs are essential to development in general. HIF-1 gene deletion in mammals causes perinatal death. It has been demonstrated that HIF-1 is essential for chondrocyte survival and enables the cells to adapt to low oxygen environments in the growth plates of bones. Human metabolism is controlled in large part by HIF. A number of medications that function as selective HIF prolyl hydroxylase inhibitors have recently been created.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V103259 | ZG-2033 | 2685739-28-8 | ZG-2033 (Compound 26) is an orally active HIF-2α agonist that exhibits nanomolar activity in a luciferase reporter assay (EC50 = 490 nM). |
|
V89017 | ZG-2291 | 2962103-40-6 | ZG-2291 is a selective inhibitor targeting FIH (hypoxia inducible factor inhibitor) and is orally active. |
|
V94304 | ZG-2305 | ZG-2305 is a potent, selective, and orally available hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6 and 2786 nM for FIH and PHD2, respectively. | |
|
V73833 | Zifcasiran sodium (ADS-007 sodium; ARO HIF2 sodium) | 2437257-12-8 | Zifcasiran sodium is a hypoxia-inducible factor (HIF) synthesis inhibitor and displays anti-tumor activity and may be utilized in the study of advanced renal cell carcinoma. |
|
V5246 | Vadadustat (PG-1016548; AKB-6548) | 1000025-07-9 | Vadadustat (formerly AKB-6548;PG-1016548; B-506;AKB6548;PG1016548;Vafseo) is a novel, potent, titratable and orally bioavailable hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor with the potential for the treatment of anemia. |
|
V20522 | Enarodustat (JTZ951) | 1262132-81-9 | Enarodustat (formerly JTZ-951; JTZ951;Enaroy) is an orally bioactive hypoxia inducible factor-proly hydroxylase (HIF-PH) inhibitorapproved (in 2020) in Japan for the treatment of anemia associated with chronic kidney disease (CKD). |
|
V30464 | Oroxylin A | 480-11-5 | Oroxylin A is an active flavonoid compound with strong anti-cancer effects. |
|
V51630 | Dimethyl-bisphenol A | 1568-83-8 | Dimethyl-bisphenol A (DMBPA) is a potent HIF-1α inhibitor. |
|
V51639 | Moracin O | 123702-97-6 | Moracin O comes from Morus alba Linn. |
|
V51640 | Moracin P | 102841-46-3 | Moracin P is a 2-arylbenzoepoxy resin extracted from Mori Cortex Radicis. |
|
V1909 | Amifostine trihydrate (WR2721) | 112901-68-5 | Amifostine trihydrate (WR2721), a phosphorylated aminosulfhydryl compound, is the first approved radioprotective drug,it is used to decrease the risk of kidney problems caused by treatment with cisplatin. |
|
V51637 | Acriflavine hydrochloride | 69235-50-3 | Acriflavine saltloride is a highly efficient fluorescent acridine dye that can be used for labeling. |
|
V0252 | Hydralazine HCl (Apresoline, Adrolazine , Apresrex) | 304-20-1 | Hydralazine HCl (Apresoline, Adrolazine , Apresrex), thehydrochloride salt of hydralazine,is a potent and direct-acting smooth muscle relaxant and vasodilatorused for the treatment of hypertension. |
|
V5194 | Chlorogenic Acid (Heriguard; NSC-407296) | 327-97-9 | Chlorogenic acid (3-O-Caffeoylquinic acid; Heriguard; NSC-407296) is a naturally occuring phenolic compound found in coffee and tea. |
|
V51626 | Fenbendazole-d3 | 1228182-47-5 | Fenbendazole-d3 is a cadmium-labeled fenbendazole. |
|
V2958 | Molidustat | 1154028-82-6 | Molidustat (formerly known as BAY 85-3934) is a novel potent inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) which stimulates erythropoietin (EPO) production and the formation of red blood cells. |
|
V51625 | Naphthofluorescein (Naphthafluorescein) | 61419-02-1 | Naphthylfluorescein inhibits the response between HIF-1 and Mint3. |
|
V32376 | Belzutifan (PT2977; MK-6482) | 1672668-24-4 | Belzutifan (PT-2977; MK-6482; PT2977; MK6482;Welireg)is a novel, selective and orally bioavailable HIF-2α (hypoxia-inducible factor 2α) inhibitor that has gained FDA approval in 2021 forthe treatment of von Hippel–Lindau disease-associated renal cell carcinoma. |
|
V2834 | Daprodustat (GSK1278863) | 960539-70-2 | Daprodustat (formerly known as GSK1278863; Duvroq) is a novel orally bioavailable hypoxia-inducible factor prolyl hydroxylase (HIF-PHI)inhibitor that has been approved for treatment of anemia associated with CKD/chronic kidney disease. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
